{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:49:24Z","timestamp":1762876164479,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010619","name":"University of Ottawa Heart Institute Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.thromres.2020.04.025","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T02:24:50Z","timestamp":1587695090000},"page":"125-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evaluation of plasminogen activator inhibitor-1 as a biomarker of unplanned revascularization and major adverse cardiac events in coronary angiography and percutaneous coronary intervention"],"prefix":"10.1016","volume":"191","author":[{"given":"Richard G.","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Simard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Di Santo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Dhaliwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Sypkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Duchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Moreland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katlyn","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Parlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Visintini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Labinaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Marbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Sarathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Bernick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Abdel-Razek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Daniel","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-1363","authenticated-orcid":false,"given":"Benjamin","family":"Hibbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2020.04.025_bb0005","first-page":"35","article-title":"The evolution of coronary stents: a brief review","volume":"30","author":"Simard","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.thromres.2020.04.025_bb0010","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","article-title":"Everolimus-eluting bioresorbable scaffolds for coronary artery disease","volume":"373","author":"Ellis","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.04.025_bb0015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijcard.2013.01.234","article-title":"Three year clinical outcomes with zotarolimus (Endeavor) drug-eluting stents in an unrestricted contemporary practice","volume":"168","author":"Giles","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2020.04.025_bb0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1004130","article-title":"Comparison of zotarolimus-eluting and everolimus-eluting coronary stents","volume":"363","author":"Serruys","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.04.025_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/187152911795945169","article-title":"Pathogenesis of neointima formation following vascular injury","volume":"11","author":"ER","year":"2011","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"10.1016\/j.thromres.2020.04.025_bb0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.04.025_bb0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat. Med."},{"key":"10.1016\/j.thromres.2020.04.025_bb0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.02.002","article-title":"Plasminogen activator inhibitor and the risk of cardiovascular disease: the Framingham Heart Study","volume":"140","author":"Tofler","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2020.04.025_bb0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.02.135","article-title":"Role of plasminogen activator inhibitor-1 in coronary pathophysiology","volume":"164","author":"Jung","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2020.04.025_bb0050","series-title":"Thrombi of Different Pathologies: Implications for Diagnosis and Treatment","first-page":"274","volume":"12","author":"Santos-Gallego","year":"2010"},{"key":"10.1016\/j.thromres.2020.04.025_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2020.04.025_bb0060","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/1479164119845123","article-title":"Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: analytical and biological considerations","volume":"16","author":"Jung","year":"2019","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.thromres.2020.04.025_bb0070","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.thromres.2020.04.025_bb0075","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1056\/NEJMoa1909406","article-title":"Five-year outcomes after PCI or CABG for left main coronary disease","volume":"381","author":"Stone","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2020.04.025_bb0080","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/01.CIR.94.9.2057","article-title":"Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities","volume":"94","author":"Juhan-Vague","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2020.04.025_bb0085","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.CIR.99.19.2517","article-title":"Thrombogenic factors and recurrent coronary events","volume":"99","author":"Moss","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2020.04.025_bb0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00001721-200101000-00003","article-title":"Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin-alpha2-antiplasmin complex is an independent predictor of coronary re-events","volume":"12","author":"Redondo","year":"2001","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2020.04.025_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000065080","article-title":"Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction","volume":"32","author":"Ganti","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.thromres.2020.04.025_bb0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jjcc.2018.05.006","article-title":"Thrombomodulin can predict the incidence of second events in patients with acute coronary syndrome: single-center, retrospective cohort study","volume":"72","author":"Kosaki","year":"2018","journal-title":"J. Cardiol."},{"key":"10.1016\/j.thromres.2020.04.025_bb0105","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1161\/ATVBAHA.107.143248","article-title":"Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease","volume":"27","author":"Robinson","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2020.04.025_bb0110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijcard.2009.02.019","article-title":"The prognostic value of biomarkers after a premature myocardial infarction","volume":"143","author":"Pineda","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2020.04.025_bb0115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jch.12047","article-title":"The impact of cigarette smoking on 24-hour blood pressure, inflammatory and hemostatic activity, and cardiovascular risk in Japanese hypertensive patients","volume":"15","author":"Yano","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.thromres.2020.04.025_bb0120","first-page":"727","article-title":"Circulating des-acyl ghrelin improves cardiovascular risk prediction in older hypertensive patients","volume":"27","author":"Yano","year":"2014"},{"key":"10.1016\/j.thromres.2020.04.025_bb0125","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000435909","article-title":"Independent predictors of major adverse events following coronary stenting over 28 months of follow-up","volume":"132","author":"Golukhova","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.thromres.2020.04.025_bb0130","unstructured":"C. Song, S. Burgess, J.D. Eicher, C.J. O'Donnell, A.D. Johnson, Causal effect of plasminogen activator inhibitor Type 1 on coronary heart disease, J. Am. Heart Assoc. 6 (2017)."},{"key":"10.1016\/j.thromres.2020.04.025_bb0135","doi-asserted-by":"crossref","first-page":"17714","DOI":"10.1038\/srep17714","article-title":"Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies","volume":"6","author":"Yarmolinsky","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2020.04.025_bb0140","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-0038-1657607","article-title":"PAI-1, obesity, insulin resistance and risk of cardiovascular events","volume":"78","author":"Juhan-Vague","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.04.025_bb0145","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvx086","article-title":"New insights into the role of adipose tissue in thrombosis","volume":"113","author":"Vilahur","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.thromres.2020.04.025_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026762","article-title":"Platelets retain high levels of active plasminogen activator inhibitor 1","volume":"6","author":"Brogren","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2020.04.025_bb0155","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2013-07-517060","article-title":"Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep\/wake cycle","volume":"123","author":"Scheer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.04.025_bb0160","series-title":"Arrhenius Temperature Dependence of In Vitro Tissue Plasminogen Activator Thrombolysis","first-page":"2953","volume":"52","author":"Shaw","year":"2007"},{"key":"10.1016\/j.thromres.2020.04.025_bb0165","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/01.ATV.18.8.1281","article-title":"Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty","volume":"18","author":"Alaigh","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2020.04.025_bb0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.4960260311","article-title":"Accelerated plasminogen activator inhibitor may prevent late restenosis after coronary stenting in acute myocardial infarction","volume":"26","author":"Inoue","year":"2003","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.thromres.2020.04.025_bb0175","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1538-7836.2007.02884.x","article-title":"Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents","volume":"6","author":"Katsaros","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.04.025_bb0180","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1055\/s-0037-1615382","article-title":"Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction","volume":"80","author":"Nordt","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.04.025_bb0185","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/eurheartj\/ehv511","article-title":"Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gr\u00fcntzig Lecture ESC 2014","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2020.04.025_bb0190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1538-7836.2004.01062.x","article-title":"Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication","volume":"3","author":"Christ","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.04.025_bb0195","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/jth.13869","article-title":"Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin","volume":"15","author":"Luo","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.04.025_bb0200","doi-asserted-by":"crossref","unstructured":"A.S. Muldowney James, R. Stringham John, E. Levy Shawn, A. Gleaves Linda, M. Eren, N. Piana Robert, E. Vaughan Douglas, Antiproliferative Agents Alter Vascular Plasminogen Activator Inhibitor-1 Expression, Arteriosclerosis, Thrombosis, and Vascular Biology 27 (2007) 400-406.","DOI":"10.1161\/01.ATV.0000254677.12861.b8"},{"key":"10.1016\/j.thromres.2020.04.025_bb0205","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2004-04-1439","article-title":"Platelets synthesize large amounts of active plasminogen activator inhibitor 1","volume":"104","author":"Brogren","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2020.04.025_bb0210","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1160\/TH15-12-0985","article-title":"Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy","volume":"115","author":"Sambola","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2020.04.025_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172558","article-title":"Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity","volume":"12","author":"Chiva-Blanch","year":"2017","journal-title":"PLoS One"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820301419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820301419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:42:21Z","timestamp":1758735741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820301419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":42,"alternative-id":["S0049384820301419"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.04.025","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of plasminogen activator inhibitor-1 as a biomarker of unplanned revascularization and major adverse cardiac events in coronary angiography and percutaneous coronary intervention","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}